Pioneering the introduction of groundbreaking medications, offering renewed hope to patients with relapse or refractory tumors.
2025-3-4As a leading explorer of research-oriented hospital models in China, GHG is dedicated to offering advanced innovative medications and treatment strategies for patients experiencing challenging relapses. Despite the many obstacles in cancer treatment, GHG stays aligned with global medical progress by promptly introducing and utilizing newly approved innovative drugs to provide patients with renewed hope. Whether dealing with lung cancer, breast cancer, cervical cancer, or other challenging tumors, GHG aids patients in attaining extended survival and improved quality of life through effective new drug implementation and tailored treatment approaches.
Here is some information regarding the introduction of innovative drugs by GHG：
|
Medication |
Indication |
Mechanism of action |
Features and Advantages |
|
Talectrectinib |
ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) |
Highly selective ROS1/NTRK inhibitors that inhibit resistant mutations such as ROS1 G2032R and L2026M. |
It effectively penetrates the blood brain barrier, manages brain metastases well, provides extensive coverage against resistant mutations, and offers a progression-free survival (PFS) of as long as 46 months. |
|
Sacituzumab Tirumotecan（TROP2-ADC） |
Advanced or metastatic triple-negative breast cancer. |
TROP2-targeted antibody-drug conjugates (ADCs) release KL610023 to induce tumor DNA damage. |
The first domestically produced TROP2-ADC in Chian, with a high DAR ratio (7.4), precisely targets tumors with minimal side effects. |
|
Ivonescimab（PD-1/VEGF bispecific antibody） |
non-small cell lung cancer (NSCLC) patients with progression after EGFR-TKI treatment |
a bispecific antibody targeting programmed cell death 1 protein and vascular endothelial growth factor with enhanced anti-tumor activity |
The world's first PD-1/VEGF bispecific antibody, targeting two pathways with a single drug, shows better efficacy than traditional combination therapies. |
|
Fulzerasib（inhibitor of the KRAS G12C mutant protein） |
KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) |
Directly inhibit the KRAS G12C mutant protein to block cancer cell proliferation signals. |
The first domestic KRAS G12C inhibitor has achieved a progression-free survival (PFS) of 9.7 months, offering significant benefits over comparable international medications. |
|
Benmelstobart |
Bevacizumab combined with anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES SCLC). |
the addition of anti-angiogenesis therapy to immunochemotherapy improves the immune microenvironment. |
The world's longest overall survival data (19.3 months) breaks through the survival bottleneck for first-line treatment of SCLC. |
|
Iparomlimab and Tuvonralimab（PD-1/CTLA-4 bispecific antibody） |
Recurrent or metastatic cervical cancer. |
Relieve immune suppression and enhance anti-tumor immunity. |
The first-ever 2:1 bispecific antibody design in the world decreases Treg activity, improves effectiveness, and results in fewer adverse effects. |
|
Glofitamab(CD20 × CD3 bispecific antibody) |
Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have undergone at least two prior lines of systemic therapy. |
Glofitamab simultaneously binds bivalently to CD20 on B-cells and monovalently to CD3 on T-cells leading to the formation of an immunological synapse between CD20-expressing B-cells and CD3-expressing T-cells. Formation of the immunological synapse leads to T-cell activation and proliferation, this approach effectively directs T cells towards tumor cells, enhances their cytotoxic capabilities, and leads to the direct elimination of the tumor. |
Successfully address the constraints of conventional treatment methods by precisely targeting tumor cells and utilizing the patient's own immune system to fight against tumors, ultimately leading to improved treatment results. |
March 2024
Glofitamab has arrived! GHG 's rapid pace brings innovative medications closer than ever
In November 2023, the National Medical Products Administration (NMPA) of China granted approval for Glofitamab, a CD20/CD3 bispecific antibody. This medication is intended for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have undergone at least two prior lines of systemic therapy. Beijing GoBroad Hospital prioritizes the medication needs of its patients and quickly sought to include this new drug in its offerings. As a result, the drug was successfully introduced to the hospital on February 22, 2024, providing access to advanced international innovations.
June 2024
Only 10 days after the groundbreaking lung cancer medication received market approval, both hospitals of GHG initiated the first use
For lung cancer patients with EGFR-TKI resistance, there is an urgent need for innovative therapies to alleviate their survival challenges. The launch of the innovative drug, Ivonescimab, has provided a new treatment option for these patients. GHG prioritizes the medication needs of its patients.. On June 2, 2024, just nine days after its approval, the innovative lung cancer drug Ivonescimab was introduced at Beijing GoBroad Hospital, marking it as the first hospital in the capital to provide this treatment. The following day, Professor Han Baohui issued the first Ivosidenib prescription in Shanghai at the Shanghai GoBroad Cancer Hospital, which is affiliated with China Pharmaceutical University.
June 2024
The first in Beijing! Beijing GoBroad Hospital has promptly launched Benmelstobart, marking a significant advancement in the first-line treatment options for patients with small cell lung cancer
On May 9, 2024, the National Medical Products Administration (NMPA) granted approval for the market launch of Benmelstobart, which is intended for the first-line treatment of patients with extensive-stage small cell lung cancer. To address the medication needs of clinical patients, Beijing GoBroad Hospital leveraged its strengths as a research-oriented hospital to promptly apply for the new drug's admission, becoming the first hospital in Beijing to offer this treatment. On June 13, the hospital successfully issued the first prescription for an inpatient, enabling small cell lung cancer patients at the facility to access this advanced and high-quality innovative drug as soon as possible, while also ensuring the clinical use of innovative medications.
August 2024
New breakthroughs in KRAS G12C targeted therapy bring renewed hope for patients with non-small cell lung cancer! Fulzerasib have been launched at GHG’s hospitals in Beijing and Shanghai.
On August 21, 2024, Fulzerasib received approval as the first KRAS G12C inhibitor in China, offering renewed hope for extended survival and enhanced quality of life for patients. Recognizing the challenges faced by patients who had therapeutic target but no drug options in the past, GHG took swift action to streamline the process for innovative drugs to be made available in its hospitals. This initiative enables patients to access these groundbreaking medications more quickly and safely, effectively meeting clinical needs. Remarkably, just 10 days after the drug's launch, Beijing GoBraod Hospital issued the first prescription in China. Following this, on September 5, Shanghai GoBroad Cancer Hospital also issued its first prescription for Fulzerasib tablets, providing advanced treatment options for patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations who have undergone at least one systemic treatment.
September 2024
Beijing's first! Iparomlimab&Tuvonralimab has landed at Gaobo, bringing new hope to cervical cancer patients.
On September 30, 2024, Iparomlimab&Tuvonralimab, developed using the innovative MabPair™ technology platform, received approval for market release. This medication is intended for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy. In October, Beijing GoBroad Hospital became the first facility in Beijing to offer this drug, demonstrating the "GHG speed" and presenting new treatment alternatives for cervical cancer patients.
November 2024
Only 5 days following the approval of Sacituzumab Tirumotecan, it has been successfully introduced in both hospitals of GHG!
The management of triple-negative breast cancer has consistently posed significant challenges within the clinical setting. Sacituzumab Tirumotecan has emerged as a promising therapeutic option, demonstrating superior efficacy compared to traditional single-agent chemotherapy, alongside a more manageable safety profile. This advancement offers renewed hope for patients diagnosed with advanced triple-negative breast cancer. GHG prioritizes the medication needs of its patients, and on November 29, 2024, shortly after receiving regulatory approval, Sacituzumab Tirumotecan was administered for the first time at Beijing GoBroad Hospital, marking it as the inaugural institution in Beijing to adopt this innovative treatment. Subsequently, on December 2, Shanghai GoBroad Cancer Hospital also successfully integrated Sacituzumab Tirumotecan into its treatment offerings. GHGois dedicated to facilitating timely and safe access to innovative pharmaceuticals for a greater number of patients, thereby addressing pressing clinical medication requirements.
February 2025
Breaking Through Drug Resistance! The new targeted drug for lung cancer, Talectrectinib, has been launched at Beijing GoBroad Hospital!
Following the recent approval of Talectrectinib for a new indication, Beijing GoBroad Hospital swiftly integrated the medication into its offerings, issuing the first prescription in Beijing on February 7, 2025. This development brings renewed hope for patients diagnosed with ROS1-positive locally advanced or metastatic non-small cell lung cancer. The introduction of Taletrectinib signifies a new era of precision treatment for lung cancer at Beijing GoBroad Hospital, emphasizing the potential to overcome drug resistance and manage brain metastases effectively. By incorporating this medication into clinical protocols, more ROS1-positive patients will have the opportunity to achieve longer survival and a higher quality of life.
